Oncaspar Solution For Injection 750iu Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Oncaspar: Solution for injection (750IU)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PEGASPARGASE (peg AS par jase) is a chemotherapy drug. This medicine is used to treat certain types of leukemia.

In-Depth Information
Select a Medication

Oncaspar 750unit/ml Solution for Injection

NDC: 000750640
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Acute Lymphocytic Leukemia (ALL)

Oncaspar 750unit/ml Solution for Injection

Reported Side Effects for Oncaspar 750unit/ml Solution for Injection

Prolonged Bleeding Time Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Bleeding In The Brain Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Pancreas Incidence:
1.0-2.0%*
Severity: SEVERE
Onset: DELAYED
High Bilirubin Level Incidence:
1.0-2.0%*
Severity: SEVERE
Onset: DELAYED
Coagulopathy Incidence:
2.0-7.0%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
2.0-11.0%*
Severity: MODERATE
Onset: DELAYED
Blood Clot Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Increased Blood Sugar Incidence:
3.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Hives Incidence:
3.0-32.0%*
Severity: MILD
Onset: RAPID
Low Blood Pressure Incidence:
3.0-32.0%*
Severity: MODERATE
Onset: RAPID
Anaphylactoid Reactions Incidence:
3.0-32.0%*
Severity: SEVERE
Onset: RAPID
Breathing Difficulties Incidence:
3.0-32.0%*
Severity: SEVERE
Onset: RAPID
Elevated Hepatic Enzymes Incidence:
3.0-11.0%*
Severity: SEVERE
Onset: DELAYED
Skin Redness Incidence:
3.0-32.0%*
Severity: MODERATE
Onset: EARLY
Laryngeal Edema Incidence:
3.0-32.0%*
Severity: SEVERE
Onset: RAPID
Skin Rash Incidence:
3.0-32.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Oncaspar

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5